Business Information
The group's principal activity is to develop, manufacture and market nucleic acid probe-based products. These products are used for the clinical diagnosis of human diseases and for screening donated human blood. The group earns through product sales, research revenue and royalty and license revenue. Product sales include sale of clinical diagnostic products and sales or rental revenue related to delivery of the group's proprietary instrument platforms for performing its diagnostic tests. Research revenue is recognized over the agreements that are earned or reimbursable costs incurred related to that agreement. Royalty revenue includes manufacture, sale or use of the group's products or technologies under license arrangements with third parties. The group has operations in the United States, France, Australia, Singapore, New Zealand, Italy, Japan and other countries. On 07-Aug-2003, it acquired additional 65.6% of molecular light technology limited.
|
|
Name |
Title
|
Email
|
| Henry Nordhoff | Chmn., CEO, Pres. | N/A | | Herm Rosenman | CFO, Sr. VP - Finance | N/A | | Brian Hansen | VP - North American Sales | N/A | | Carl Hull | COO, Exec. VP | N/A | | Christina Yang | Sr. VP - Clinical, Regulatory, Quality | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 354,764 | 59,498 | | 2005 | 305,965 | 60,089 | | 2004 | 269,707 | 54,575
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
